BAM
ALXN

Barrett Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Barrett Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$12K – 384
2017
Q2 		$12K Hold
100
– – ﹤0.01% 325
2017
Q1 		$12K Hold
100
– – ﹤0.01% 313
2016
Q4 		$12K Hold
100
– – ﹤0.01% 315
2016
Q3 		$12K Buy
100
+5
+5% +$644 ﹤0.01% 286
2016
Q2 		$11K Hold
95
– – ﹤0.01% 289
2016
Q1 		$13K Buy
+95
New +$13.9K ﹤0.01% 306

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Barrett Asset Management's ALXN Position: Q3 2017 in Review

Barrett Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 100 shares — an estimated $12K sold.

Barrett Asset Management first reported a position in ALXN in Q1 2016 and held it in 6 quarters. The position peaked at $13K in Q1 2016. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Barrett Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Barrett Asset Management sold 100 Alexion Pharmaceuticals shares in Q3 2017, an estimated $12K.
  • Barrett Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Barrett Asset Management's Alexion Pharmaceuticals position peaked at $13K in Q1 2016.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Barrett Asset Management's 13F filing for Q3 2017, filed 8 Nov 2017.